Progress in Defining Optimal Treatment Outcome in Schizophrenia

No abstract is available for this paper.

• Publication year

  2010

• Venue

  CNS Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.2165/11530250-000000000-00000PMID 20030416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The concepts of remission and recovery in schizophrenia

  2011cited by this paper
• Negative symptoms in schizophrenia: avolition and Occam's razor.

  2010cited by this paper
• Elementary neurocognitive function, facial affect recognition and social-skills in schizophrenia.

  2009cited by this paper
• A review of instruments for measuring functional recovery in those diagnosed with psychosis.

  2009cited by this paper
• Association between symptomatic remission and functional outcome in first-episode schizophrenia.

  2009cited by this paper
• The predictive value of measures of social cognition for community functioning in schizophrenia: Implications for neuropsychological assessment

  2009cited by this paper
• Psychiatric comorbidities and schizophrenia.

  2009cited by this paper
• Cognitive remediation: a promising tool for the treatment of schizophrenia

  2008cited by this paper
• Symptom remission in first episode patients.

  2008cited by this paper
• Sedation as a side effect of the treatment of mental disorders.

  2008cited by this paper
• Tardive dyskinesia and new antipsychotics

  2008cited by this paper
• Subjective effects of antipsychotic drugs and their relevance for compliance and remission

  2008cited by this paper
• Comparative remission rates of schizophrenic patients using various remission criteria.

  2008cited by this paper
• Predictors of Remission and Recovery in a First-Episode Schizophrenia Spectrum Disorder Sample: 2-Year Follow-up of the OPUS Trial

  2008cited by this paper
• UC San Francisco UC San Francisco Previously Published Works Title The pipeline and future of drug development in schizophrenia

  2008cited by this paper
• Definitions of the Term ‘Recovered’ in Schizophrenia and Other Disorders

  2008cited by this paper
• Schizophrenia: From developmental deviance to dopamine dysregulation

  2008cited by this paper
• Subjective and objective quality of life in schizophrenia.

  2008cited by this paper
• Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.

  2008cited by this paper
• A review of instruments developed to measure outcomes for carers of people with mental health problems

  2008cited by this paper
• New generation antipsychotic drugs and compliance behaviour

  2008cited by this paper
• Remission in the outpatient care of schizophrenia: 3-Year results from the Schizophrenia Outpatients Health Outcomes (SOHO) Study in France

  2008cited by this paper
• Recent advances in shared decision making for mental health

  2008cited by this paper
• Relationship of cognition and psychopathology to functional impairment in schizophrenia.

  2008cited by this paper
• Do consumers use the word "recovery"?

  2008cited by this paper
• Functional outcomes in schizophrenia.

  2008cited by this paper
• Emerging drugs for schizophrenia

  2008cited by this paper
• Extrapyramidal side-effects of antipsychotics in a randomised trial

  2008cited by this paper
• Factors Involved in Outcome and Recovery in Schizophrenia Patients Not on Antipsychotic Medications: A 15-Year Multifollow-Up Study

  2007cited by this paper
• Early Use of Clozapine for Poorly Responding First-Episode Psychosis

  2007cited by this paper
• Unanswered questions in schizophrenia clinical trials.

  2007cited by this paper
• Molecular targets for treating cognitive dysfunction in schizophrenia.

  2007cited by this paper
• Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders.

  2007cited by this paper
• On the concept of remission in schizophrenia

  2007cited by this paper
• Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: Prevalence and associations in a cross-sectional study

  2007cited by this paper
• Remission criteria for schizophrenia: evaluation in a large naturalistic cohort.

  2007cited by this paper
• Social Cognition and Neurocognition: Effects of Risperidone, Olanzapine, and Haloperidol.

  2007cited by this paper
• Negative symptoms of schizophrenia: a problem that will not go away

  2007cited by this paper
• How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia.

  2007cited by this paper
• Performance-based measures of functional skills: usefulness in clinical treatment studies.

  2007cited by this paper
• Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

  2007cited by this paper
• Remission in schizophrenia: applying recent consensus criteria to refine the concept.

  2007cited by this paper
• Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study

  2007cited by this paper
• Rationale for Emphasis on Management over Treatment of Schizophrenia in Clinical Practice

  2007cited by this paper
• Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.

  2007cited by this paper
• Social cognitive impairments in first episode psychosis.

  2007cited by this paper
• The Clinical Relevance of Percentage Improvements on the PANSS Score

  2007cited by this paper
• Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul‐de‐sac?

  2007influential reference
• Measuring Illness Management Outcomes: A Psychometric Study of Clinician and Consumer Rating Scales for Illness Self Management and Recovery

  2007cited by this paper
• Defining ‘Response’ in Antipsychotic Drug Trials: Recommendations for the Use of Scale-Derived Cutoffs

  2007cited by this paper
• EPS Profiles: The Atypical Antipsychotics: Are Not All the Same

  2007cited by this paper
• Treatment-resistant schizophrenia.

  2007cited by this paper
• What the CATIE study means for clinical practice.

  2006cited by this paper
• The NIMH-MATRICS consensus statement on negative symptoms.

  2006cited by this paper
• Schizophrenia: From Neuroimaging to Neuroscience

  2006cited by this paper
• Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?

  2006cited by this paper
• Tardive dyskinesia circa 2006.

  2006cited by this paper
• Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

  2006cited by this paper
• The Concepts of Remission and Recovery in Schizophrenia

  2006cited by this paper
• Standardized remission criteria in schizophrenia

  2006cited by this paper
• Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness.

  2006cited by this paper
• Commentary: disquieting aspects of the recovery paradigm.

  2006cited by this paper
• The top ten concerns about recovery encountered in mental health system transformation.

  2006influential reference
• Standardized remission criteria in schizophrenia

  2006influential reference
• Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

  2006cited by this paper
• Linking the PANSS, BPRS, and CGI: Clinical Implications

  2006cited by this paper
• Drug initiatives to improve cognitive function.

  2006influential reference
• Negative symptoms and cognitive deficits: what is the nature of their relationship?

  2006cited by this paper
• The Australian experience of deinstitutionalization: interaction of Australian culture with the development and reform of its mental health services

  2006cited by this paper
• The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions.

  2006cited by this paper
• Commentary: all we are saying is give people with mental illnesses a chance.

  2006cited by this paper
• Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia.

  2006influential reference
• Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim.

  2006cited by this paper
• Validation of remission criteria for schizophrenia.

  2006cited by this paper
• Improving adherence to antipsychotic pharmacotherapy.

  2006cited by this paper
• Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.

  2006cited by this paper
• Augmentation Strategies of Clozapine With Antipsychotics in the Treatment of Ultraresistant Schizophrenia

  2006cited by this paper
• Barriers to employment for people with schizophrenia.

  2006cited by this paper
• The Relative Sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in Antipsychotic Drug Trials

  2006cited by this paper
• Relapse prevention and recovery in the treatment of schizophrenia.

  2006cited by this paper
• Commentary: all we are saying is give people with mental illnesses a chance.

  2006cited by this paper
• Examining the latent structure of negative symptoms: is there a distinct subtype of negative symptom schizophrenia?

  2005cited by this paper
• Long-Term Outcome of Patients with Schizophrenia: A Review

  2005cited by this paper
• Health status of individuals with serious mental illness.

  2005cited by this paper
• Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis.

  2005cited by this paper
• Special Section on the GAF: Selection of Outcome Assessment Instruments for Inpatients With Severe and Persistent Mental Illness

  2005cited by this paper
• Remission: what's in a name?

  2005cited by this paper
• First-Episode Psychosis, Early Intervention, and Outcome: What Have We Learned?

  2005cited by this paper
• Measuring the effectiveness of outpatient care.

  2005cited by this paper
• Recovery from schizophrenia: a concept in search of research.

  2005cited by this paper
• History of the discovery and clinical introduction of chlorpromazine.

  2005cited by this paper
• Social context and health consequences of the antipsychotics introduction.

  2005cited by this paper
• At issue: is natural selection rendering schizophrenia less severe?

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• Schizophrenia and increased risks of cardiovascular disease.

  2005cited by this paper
• Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy.

  2005influential reference
• Defining and measuring clinical effectiveness in the treatment of schizophrenia.

  2005cited by this paper
• Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.

  2005cited by this paper
• Longitudinal Studies of Outcome and Recovery in Schizophrenia and Early Intervention: Can They Make a Difference?

  2005cited by this paper
• Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.

  2005cited by this paper

• Associations between cardiorespiratory fitness, body mass index, and reward processing in first-episode schizophrenia

  2025cites this paper
• Shared Decision-Making in the Management of Schizophrenia: A Systematic Review

  2025cites this paper
• Second-Generation Antipsychotic Long-Acting Injection Reduced the Time of Restrictive Interventions in Patients With Schizophrenia

  2022cites this paper
• Effect of quetiapine on inflammation and immunity: a systematic review

  2022cites this paper
• The Dutch Recovering Quality of Life questionnaire (ReQoL) and its psychometric qualities

  2020cites this paper
• Psychosocial interventions in schizophrenia: Focus on guidelines

  2020cites this paper
• Using the CHIME Personal Recovery Framework to Evaluate the Validity of the MHRM-10 in Individuals with Psychosis

  2020cites this paper
• The Dutch Recovering Quality of Life questionnaire (ReQoL) and its psychometric qualities

  2020cites this paper
• Recovery from schizophrenia: is it possible?

  2018cites this paper
• First-generation antipsychotic haloperidol: optical absorption measurement and structural, electronic, and optical properties of its anhydrous monoclinic crystal by first-principle approaches

  2018cites this paper
• Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern

  2018cites this paper
• Psychiatric symptoms mediate the effects of neurological soft signs on functional outcomes in patients with chronic schizophrenia: A longitudinal path-analytic study.

  2017cites this paper
• Vitamin-D Deficiency As a Potential Environmental Risk Factor in Multiple Sclerosis, Schizophrenia, and Autism

  2017cites this paper
• Behavioural Interventions for Weight Management Among Patients with Schizophrenia

  2017cites this paper
• Personalizing Antipsychotic Treatment of Schizophrenia: Monitoring Plasma Levels for Improved Treatment Decisions

  2017cites this paper
• Lifetime psychopathological dimensions, cognitive impairment and functional outcome in psychosis.

  2017cites this paper
• A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD).

  2016cites this paper
• Chapter 6 – Antipsychotics

  2016cites this paper
• Motivational Deficits in Schizophrenia

  2016cites this paper
• Quality of Life, Cognition, and Social Cognition in Schizophrenia

  2016cites this paper
• Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use

  2016cites this paper
• Quality of life and functioning in first‐episode psychosis Chinese patients with different antipsychotic medications

  2016cites this paper
• New Targets for the Management of Schizophrenia

  2015cites this paper
• Investigating the functional significance of genome-wide variants associated with antipsychotic treatment response in schizophrenia

  2015cites this paper
• Clinical and Functional Outcomes in People With Schizophrenia With a High Sense of Well-Being

  2015cites this paper
• Psychosocial functioning in relation to symptomatic remission: A longitudinal study of first episode schizophrenia

  2015cites this paper
• Self-help interventions for psychosis: a meta-analysis.

  2015cites this paper
• Dissecting Shared and Unique Neural Circuitry Underlying Negative Symptoms, Social Cognition, and Functional Outcome in Schizophrenia

  2015cites this paper
• Pharmacological treatment , rehabilitative and psychosocial psychotherapy

  2015cites this paper
• The Specific Level of Functioning Scale: construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community.

  2014cites this paper
• Spanish cross-cultural adaptation and psychometric properties of the Schizophrenia Quality of Life short-version questionnaire (SQoL18) in 3 middle-income countries: Bolivia, Chile and Peru.

  2014cites this paper
• Determinants of patient-rated and clinician-rated illness severity in schizophrenia.

  2014cites this paper
• Recent advances in understanding schizophrenia

  2014cites this paper
• Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: findings from the NIMH CATIE study.

  2014cites this paper
• Schizophrenia--time to commit to policy change.

  2014cites this paper
• Treatingthe MentallyIllJuvenile SexOffender

  2014cites this paper
• Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials

  2014cites this paper
• [Remission and recovery: new hopes--realistic aims in the therapy for schizophrenia].

  2014cites this paper
• [Social functioning and quality of life in schizophrenia patients --relationship with symptomatic remission and duration of illness].

  2014cites this paper
• Antipsychotic treatment of schizophrenia: an update.

  2014cites this paper
• An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia

  2013cites this paper
• Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study.

  2013cites this paper
• Studies on the Association between Genetic Polymorphisms and Clozapine Drug Response in Treatment Resistant Schizophrenia.

  2013cites this paper
• Validation of an abbreviated quality of life scale for schizophrenia.

  2013cites this paper
• Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system.

  2012cites this paper
• Effects of modafinil on cognitive functions in first episode psychosis

  2012cites this paper
• Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation.

  2012cites this paper
• To poly(I:C) or not to poly(I:C): advancing preclinical schizophrenia research through the use of prenatal immune activation models.

  2012cites this paper
• Self-stigma and its relationship with insight, demoralization, and clinical outcome among people with schizophrenia spectrum disorders.

  2012cites this paper
• Beyond Pharmacotherapy: Understanding the Links between Obesity and Chronic Mental Illness

  2012cites this paper
• Clinical Manual for Treatment of Schizophrenia

  2012cites this paper
• "Selbst- und fremdberichtete Krankheitseinsicht, Symptomatik und Lebensqualität bei Patienten mit Störungen aus dem schizophrenen Formenkreis"

  2012cites this paper
• Cognition and communication dysfunctions in early-onset schizophrenia: effect of risperidone.

  2012cites this paper
• Environmental and genetic modulation of dopaminergic development

  2011cites this paper
• Assessing attention in the zebrafish: Are we there yet?

  2011cites this paper
• Management of Schizophrenia in Late Life with Antipsychotic Medications

  2011cites this paper
• Density of striatal D2 receptors in untreated first-episode psychosis: an I123-IBZM SPECT study.

  2011cites this paper
• Resultados clínicos relevantes en esquizofrenia: remisión y recuperación

  2011cites this paper
• Treatment resistant schizophrenia and response to antipsychotics: a review.

  2011cites this paper
• Measuring psychosocial outcomes in schizophrenia patients

  2011cites this paper
• Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia.

  2011cites this paper
• Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection

  2011cites this paper
• Is personal and social functioning associated with subjective quality of life in schizophrenia patients living in the community?

  2011cites this paper
• ASSESSMENT OF GENETIC AND ENVIRONMENTAL FACTORS IN ANIMAL MODELS OF SCHIZOPHRENIA

  2011cites this paper
• Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia.

  2011cites this paper
• Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment

  2011cites this paper
• The concepts of remission and recovery in schizophrenia

  2011cites this paper
• Clinical meaningful outcomes in schizophrenia: remission and recovery.

  2011cites this paper
• Country differences in patient characteristics and treatment in schizophrenia: data from a physician-based survey in Europe

  2011cites this paper
• Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future.

  2010cites this paper
• Late Prenatal Immune Activation in Mice Leads to Behavioral and Neurochemical Abnormalities Relevant to the Negative Symptoms of Schizophrenia

  2010cites this paper
• Current awareness in human psychopharmacology

  2010cites this paper
• Schizophrenia as a disorder of too little dopamine : implications for symptoms & treatment association and limbic areas of the cortex converge on differ

  2008influential citation